首页> 外文期刊>European Journal of Medicinal Chemistry: Chimie Therapeutique >Synthesis and biological evaluation of new MET inhibitors with 1,6-naphthyridinone scaffold
【24h】

Synthesis and biological evaluation of new MET inhibitors with 1,6-naphthyridinone scaffold

机译:用1,6-萘醌支架的新符号抑制剂的合成与生物学评价

获取原文
获取原文并翻译 | 示例
           

摘要

A potent and novel MET inhibitor, 5-((4((2-amino-3-chloropyridin-4-yl)oxy)-3-fluorophenyl)amino)-3-(4-fluorophenyl)-1,6-naphthyridin-4(1H)-ones (8), was designed and synthesized via a scaffold-hopping strategy of a 2,7-naphthyridinone MET kinase inhibitor 7. Lead compound 8 had good potency (IC50 of 9.8 nM), but unfavorable pharmacokinetic profiles (F = 12%, CL = 5.0 L/h/kg). Systematic structural optimization of compound 8 resulted in 9g (MET, IC50 - of 9.8 nM) with a comparable MET potency to that of compound 2 and a favorable pharmacokinetic profile (F= 63%, CL = 0.12 L/h/kg). Further study of the derivatization of N(1) amine group of 9g led to the discovery of 23a with good MET potency (IC50 of 7.1 nM), promising VEGFR-2 selectivity (3226-fold), and a markedly drug-likeness improvement (F= 57.7%, CL = 0.02 L/h/kg). The excellent VEGFR-2 selectivity and favorable drug-likeness of 23g suggest that the 1,6-naphthyridine moiety could be used as a new scaffold for kinase inhibitor discovery. (C) 2019 Elsevier Masson SAS. All rights reserved.
机译:一个强有力的和新颖MET抑制剂,5 - ((4-((2-氨基-3-氯吡啶-4-基)氧基)-3-氟苯基)氨基)-3-(4-氟苯基)-1,6-二氮杂萘4(1H) - 酮(8),设计并通过2,7-萘啶酮MET激酶抑制剂7.铅化合物8的支架跳频策略合成具有良好效力(9.8 nM的IC 50为),但不利的药代动力学曲线( F = 12%,CL = 5.0升/小时/千克)。 (MET,IC50 - 9.8纳米)导致9克化合物8的系统的结构优化与可比MET效力化合物2和有利的药代动力学分布的(F = 63%,CL = 0.12升/小时/千克)。 N的衍生化的进一步研究(1)将1.9g胺基导致23a的发现具有良好MET效力(IC 50 7.1纳米),有前途的VEGFR-2选择性(3226倍),以及显着类药性的改善( F = 57.7%,CL = 0.02升/小时/千克)。优异的VEGFR-2选择性和23克的有利药物相似性表明,1,6-二氮杂萘基部分可被用作激酶抑制剂发现了新的支架。 (c)2019年Elsevier Masson SAS。版权所有。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号